Spinal Stimulation for Depression
(MOSPID Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for major depressive disorder (MDD) using transcutaneous spinal direct current stimulation (tsDCS). The goal is to determine if stimulating specific spinal pathways can improve depression symptoms. Researchers aim to identify the optimal dose and its effects on brain signals associated with depression. Suitable participants have experienced a current episode of MDD for at least four weeks but not more than two years and are on stable antidepressant medication. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative treatment.
Will I have to stop taking my current medications?
The trial requires participants to be on a stable dose of an FDA-approved antidepressant for at least 8 weeks before joining. However, you cannot participate if you are using anticonvulsant medications, calcium channel blockers, or need chronic pain medication like NSAIDs and opiates.
What prior data suggests that this spinal stimulation technique is safe for treating depression?
Research has shown that transcutaneous spinal direct current stimulation (tsDCS) is generally safe. In over 18,000 sessions with both healthy individuals and those with neurological or mental health conditions, no serious health issues occurred. This indicates that participants did not experience major problems from the treatment.
Studies also indicate that tsDCS is well-tolerated. In trials involving individuals with chronic pain, participants managed the treatment without significant issues. These findings suggest that tsDCS is a promising and safe option for exploring new treatments for depression.12345Why do researchers think this study treatment might be promising for depression?
Researchers are excited about transcutaneous spinal direct current stimulation (tsDCS) for treating depression because it offers a non-invasive approach, unlike traditional treatments like antidepressant medications and psychotherapy. This method involves applying a mild electrical current to the spinal cord, which could modulate neural pathways linked to mood regulation. Unlike medications, which can take weeks to become effective and often have side effects, tsDCS has the potential to provide quicker relief with fewer side effects. Additionally, this technique might benefit patients who haven't responded well to conventional treatments, offering a new avenue of hope for those with treatment-resistant depression.
What evidence suggests that transcutaneous spinal direct current stimulation might be an effective treatment for major depressive disorder?
Research has shown that a new method called transcutaneous spinal direct current stimulation (tsDCS) could help treat major depressive disorder (MDD). A small initial study found that tsDCS is safe, easy to handle, and may assist with MDD. Early results suggest that tsDCS can change how certain brain areas process signals from the body, potentially improving depression symptoms. Other studies indicate that similar types of stimulation can reduce depression symptoms and work well with medications. In this trial, participants will receive different active doses of tsDCS or a sham treatment to evaluate its effectiveness. Overall, tsDCS presents a promising new option for people with MDD.56789
Who Is on the Research Team?
Francisco Romo-Nava, MD, PhD
Principal Investigator
Lindner Center of Hope/ University of Cincinnati
Are You a Good Fit for This Trial?
This trial is for adults with Major Depressive Disorder (MDD) who may benefit from a non-invasive treatment. Participants should be interested in exploring new therapeutic options that involve spinal cord stimulation to manage their depression symptoms.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive transcutaneous spinal direct current stimulation (tsDCS) to evaluate spinal and brain-based SIPs target engagement markers in MDD
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Transcutaneous Spinal Direct Current Stimulation
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Cincinnati
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator